Dear Patient,

Amolyt Pharma announced that the company has entered into an agreement to be acquired by AstraZeneca (announcement attached). The transaction is expected to close in the third quarter of 2024.

Amolyt Pharma continues to run its business operations as usual and is committed to executing all its development activities. There are no changes to Amolyt’s relationships and agreements with any of its partners and research collaborators. The CALYPSO study will continue to operate as planned and physician participants will remain the same.

Alexion, AstraZeneca Rare Disease, is a worldwide leader in the development of innovative treatments for rare diseases with 5 approved drugs and multiple others in clinical trials for the treatment of rare diseases. They have established a strong presence in nephrology and bone metabolism. Alexion shares Amolyt’s vision for eneboparatide and its potential to benefit patients with hypoparathyroidism and has the expertise and resources to move Amolyt’s programs forward rapidly for the potential benefit of patients who desperately need access to new treatments. This is an exciting next phase in the development of much needed medication for hypoparathyroidism patients.

Dr Mark Sumeray
Chief Medical Officer